Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

Summary

This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect clinical decision making.

The study will evaluate risk factors and co-variants, including genetic variants that are associated with disease progression such as pain, inflammation, organ dysfunction, disability and quality of life.

Conditions

• Chronic Pancreatitis
• Inflammatory Bowel Diseases
• Hepatitis
• NASH - Nonalcoholic Steatohepatitis
• Acute Pancreatitis
• Rheumatoid Arthritis
• Diabetes Mellitus
• Dyslipidemias
• Multiple Sclerosis
• Irritable Bowel Syndrome
• Chronic Pain
• Chronic Disease
• Chronic Kidney Diseases
• Crohn Disease
• Celiac Disease
• Biliary Cirrhosis
• Bile Acid Synthesis Defect
• Gastritis
• Cholecystitis
• Cholelithiases
• IPMN
• Cyst Pancreas
• Cystic Fibrosis
• Pancreatic Exocrine Insufficiency
• Diarrhea Chronic
• Constipation - Functional
• Constipation Chronic Idiopathic

Interventions

OTHER

venipuncture

Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.

BEHAVIORAL

Questionnaires

PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.

OTHER

Additional Sample Collections

We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.

Sponsors & Collaborators

• University of Pittsburgh

  lead OTHER

Principal Investigators

• David C Binion, MD · University of Pittsburgh

Eligibility

Min Age

12 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-11-01

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• United States

Study Locations